Verdiva cans mid-stage obesity trial of GLP-1 pill, citing 'market evolution'

Phase 2negativeNegative

AI Analysis

Summary

Verdiva Bio has terminated a Phase 2 trial of its GLP-1 pill for obesity, citing market evolution. The company is one of well-funded private biotechs in the competitive obesity drug market.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Phase 2 trial terminated

Importance:5/10

Sentiment:

-0.60

obesityGLP-1trial terminationdrug developmentclinical trial

Read the original article

Published by Endpoints News on October 13, 2026 5:42 PM

Read Original